Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Deficit)

v3.22.2.2
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Conversion Of Convertible Debt
Previously Reported
Revision of Prior Period, Adjustment
Common Stock
Common Stock
Conversion Of Convertible Debt
Common Stock
Previously Reported
Common Stock
Revision of Prior Period, Adjustment
Additional Paid-in Capital
Additional Paid-in Capital
Conversion Of Convertible Debt
Additional Paid-in Capital
Previously Reported
Additional Paid-in Capital
Revision of Prior Period, Adjustment
Stockholders’ Accumulated Deficit
Stockholders’ Accumulated Deficit
Previously Reported
Redeemable Convertible Preferred Stock
Previously Reported
Redeemable Convertible Preferred Stock
Revision of Prior Period, Adjustment
Balance, at beginning of period at Dec. 31, 2020                             $ 43,272 $ (43,272)
Balance, at beginning of period (in shares) at Dec. 31, 2020                             30,120,057 (30,120,057)
Balance, at beginning of period at Dec. 31, 2020 $ (26,695)   $ (69,967) $ 43,272 $ 3     $ 3 $ 54,097   $ 10,828 $ 43,269 $ (80,795) $ (80,795)    
Balance, at beginning of period (in shares) at Dec. 31, 2020         32,949,507   4,910,555 28,038,952                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Exercise of Common Warrants [1] 646               646              
Exercise of Common Warrants (in shares) [1]         69,232                      
Issuance of stock for commitment shares and Series C redeemable convertible preferred stock upon exercise of Series C warrants [1] 14,068               14,068              
Issuance of stock for commitment shares and Series C redeemable convertible preferred stock upon exercise of Series C warrants (in shares) [1]         1,756,525                      
Business Combination and PIPE Financing 109,805       $ 4       109,801              
Business Combination and PIPE Financing (in shares)         37,843,390                      
Warrants issued in connection with the Convertible Note 14,522               14,522              
Issuance of common stock warrants 433               433              
Exercise of stock options [1] 552               552              
Exercise of stock options (in shares) [1]         1,135,918                      
Vesting of restricted stock units, net of taxes (in shares)         17,168                      
Stock-based compensation expense 1,545               1,545              
Conversion of convertible notes payable   $ 10,089               $ 10,089            
Conversion of convertible notes payable (in shares)           1,055,388                    
Net income (loss) (122,955)                       (122,955)      
Balance, at end of period at Sep. 30, 2021 2,010       $ 7       205,753       (203,750)      
Balance, at end of period (in shares) at Sep. 30, 2021         74,827,128                      
Balance, at beginning of period at Jun. 30, 2021 39,522       $ 7       193,804       (154,289)      
Balance, at beginning of period (in shares) at Jun. 30, 2021         73,248,111                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Exercise of stock options 511               511              
Exercise of stock options (in shares)         506,461                      
Vesting of restricted stock units, net of taxes (in shares)         17,168                      
Stock-based compensation expense 1,349               1,349              
Conversion of convertible notes payable   $ 10,089               $ 10,089            
Conversion of convertible notes payable (in shares)           1,055,388                    
Net income (loss) (49,461)                       (49,461)      
Balance, at end of period at Sep. 30, 2021 2,010       $ 7       205,753       (203,750)      
Balance, at end of period (in shares) at Sep. 30, 2021         74,827,128                      
Balance, at beginning of period at Dec. 31, 2021 25,212       $ 8       206,768       (181,564)      
Balance, at beginning of period (in shares) at Dec. 31, 2021         75,062,642                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of stock for commitment shares and Series C redeemable convertible preferred stock upon exercise of Series C warrants 851               851              
Issuance of stock for commitment shares and Series C redeemable convertible preferred stock upon exercise of Series C warrants (in shares)         299,491                      
Exercise of stock options $ 129               129              
Exercise of stock options (in shares) 363,823       363,823                      
Vesting of restricted stock units, net of taxes $ (114)               (114)              
Vesting of restricted stock units, net of taxes (in shares)         277,352                      
Stock-based compensation expense 3,878               3,878              
Net income (loss) 23,751                       23,751      
Balance, at end of period at Sep. 30, 2022 53,707       $ 8       211,512       (157,813)      
Balance, at end of period (in shares) at Sep. 30, 2022         76,003,308                      
Balance, at beginning of period at Jun. 30, 2022 52,617       $ 8       209,191       (156,582)      
Balance, at beginning of period (in shares) at Jun. 30, 2022         75,610,103                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of stock for commitment shares and Series C redeemable convertible preferred stock upon exercise of Series C warrants 851               851              
Issuance of stock for commitment shares and Series C redeemable convertible preferred stock upon exercise of Series C warrants (in shares)         299,491                      
Exercise of stock options 6               6              
Exercise of stock options (in shares)         58,819                      
Vesting of restricted stock units, net of taxes (6)               (6)              
Vesting of restricted stock units, net of taxes (in shares)         34,895                      
Stock-based compensation expense 1,470               1,470              
Net income (loss) (1,231)                       (1,231)      
Balance, at end of period at Sep. 30, 2022 $ 53,707       $ 8       $ 211,512       $ (157,813)      
Balance, at end of period (in shares) at Sep. 30, 2022         76,003,308                      
[1] Share amounts have been retroactively restated to give effect to the recapitalization transaction